Medtronic raises annual profit forecast on medical devices strength-February 2024-www.financetom.com

Medtronic raises annual profit forecast on medical devices strength

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Medtronic raises annual profit forecast on medical devices strength

Aug 20, 2024 4:16 AM

Aug 20 (Reuters) - Medtronic ( MDT ) lifted its annual

profit forecast on Tuesday, banking on sustained demand for its

medical devices following a rise in surgeries and procedures.

The company expects profit of between $5.42 and $5.50

per share for the fiscal year 2025, compared with its earlier

forecast of $5.40 to $5.50.

(Reporting by Sriparna Roy and Puyaan Singh in Bengaluru;

Editing by Sriraj Kalluvila and Devika Syamnath)

Previous page： Hospital Chain Operator HCA Healthcare Says Positive Q2 Earnings Reflect Strong Demand For Services, Issues Upbeat Annual Outlook Next page： Cellectar Shares Fall as Updated Data For Investigational Radiotherapy Shows Drop in Major Response Rate

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Hospital Chain Operator HCA Healthcare Says Positive Q2 Earnings Reflect Strong Demand For Services, Issues Upbeat Annual Outlook

Jul 23, 2024

On Tuesday, HCA Healthcare Inc. ( HCA ) reported second-quarter revenues of $17.49 billion, up from $15.86 billion a year ago and beating the consensus of $17.05 billion. The hospital chain reported adjusted EPS of $5.50, up from $4.29 a year ago, beating the consensus of $5.36. “The company’s results for the second quarter were positive and reflected strong demand for...

Cellectar Shares Fall as Updated Data For Investigational Radiotherapy Shows Drop in Major Response Rate

Jul 23, 2024

01:26 PM EDT, 07/23/2024 (MT Newswires) -- Cellectar Biosciences ( CLRB ) shares were down nearly 19% in recent Tuesday trading after the company released updated data for its investigational radiotherapy Iopofosine I 131, showing a drop in major response rate. As of the May 31 cutoff, Iopofosine I 131 was found to have a major response rate of 56.4%...

Sector Update: Consumer

Jul 23, 2024

01:24 PM EDT, 07/23/2024 (MT Newswires) -- Consumer stocks were softer Tuesday afternoon, with the Consumer Staples Select Sector SPDR Fund (XLP) shedding 0.2% and the Consumer Discretionary Select Sector SPDR Fund (XLY) fractionally lower. Redbook US same-store sales rose by 4 .9% from a year earlier in the week ended July 20 after a 4.8% year-over-year increase in the...

Why Transcode Therapeutics (RNAZ) Stock Is Down 60%

Jul 23, 2024

Transcode Therapeutics Inc ( RNAZ ) shares are trading lower by 62% to $0.30 during Tuesday’s session after the company announced pricing of its public offering. The public offering of 10 million shares of its common stock will be at $0.30 per share, aiming to raise $3 million before deducting expenses. The offering is set to close on July 24,...